Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
strong no
Merry Christmas and let's have a profitable 2008
Ron
Yes!
Is this what they call white collar crime?
legal fees
By not asking for legal fees at this stage, have we offered and incentive to pay vs appeal as we would have ask for legal fees on appeal. avoiding interest cost are no incentive when the value of dollar is slipping. Just a thought as to why are legal group decide not to ask for legal cost.
Ron
The delay if it happens would be caused by lawyers and any notes required.
recaf may work, but does it work to the degree that makes it commercialy viable at the present time? The last refinemewnts can take time so we need patience.
60,000 shares
Ron
You have been proven right and we give you credit, but please quit rubbing it in!! Many of are hurting and can"t appreciate your gloating. With your declared intelligence I hope you can understand.
Ron
I now know why the price dropped after the signed agreement. I guess it may also explain the increase in positive coments on the board before the breakup of the GE deal so they could get out first. I was dumb enought to buy in at the wrong time and the wrong price.
I was thinking more of employees that were no longer with the company.
Ron
They may be on a fishing exhibition but they appear to have someone telling them where to fish. Could an ex employee with an ax or an agenda be pointing the way?
Ron
I was a division president of a major company and retired early to teach school. I taught in a private Catholic school that had open enrollment. Every year at the completion of the school year 2 or 3 percent of the student with behavior problems were told they could not return. As small as that number sounds it eliminates 90% of the disipkine problems. I know that I made a difference in students life and found teaching very satisfying. At present I am working with GED students at a county jail and find they also are willing to work and in many cases change their life. Teachers can make a difference if they care.
bizjournals.com
Abbott to market prostate cancer screen developed by Phila. firm
Monday March 12, 10:35 am ET
MacroArray Technologies said Monday that Abbott Laboratories will market a new test MacroArray has developed for prostate cancer.
MacroArray said its test "may offer advantages over" the widely used prostate-specific antigen tests, which, when they register a high level, do not necessarily mean cancer. According to the National Cancer Institute, 70 percent to 75 percent of men who have biopsies after PSA tests test negative for prostate cancer.
In blinded studies of 533 patients, the company said, 21 percent of patients who tested positive under the MacroArray test did not have prostate cancer.
MacroArray of Philadelphia said its PCADM-1 urine test looks for a gene that is "over-expressed only in malignant prostate tissue."
The PCADM-1 gene was discovered by researchers at the Drexel University College of Medicine in Philadelphia, the company said.
Michael J. Wassil, the CEO of the privately held company, said prostate cancer screening is a $1 billion a year industry worldwide. Wassil expects his company's test to be used side-by-side with PSA testing at first, for verification purposes.
He declined to provide financial details on the deal with Abbott, which will adapt the test to its own equipment and market it.
Wassil said the deal with Abbott (NYSE:ABT - News) of Abbott Park, Ill., is nonexclusive and MacroArray could strike agreements with other firms.
Published March 12, 2007 by the Philadelphia Business Journal
The final 5% of process development is often the hardest. It might save you a lot of grief by waiting for an official announcement before you go all in.
Did you ever watch deal or no deal? Bocx like other emerging biotechs has a constant need for cash to continue. They need ABT to provide it or enter into other agreements or borrowing with its dillution. Products developed but not in the market place produce no revenue. Bocx needs a source of cash. Until they get it the stock price will remain low.
Was that the ISV you told would sign an agreement today?
kag,does monitoring this board seem at all like teaching Freshman, with all the childish remarks?
enough!
Corp you have transition from an asset to a liability. Please return to your old construtive approach.
When I was division president of a fortune 500 company my bonus and stock option plans were based on results for the previous period. This managment team seems to be getting rewards for what they hope to accomplish in the future. I would like them to be rewarded in a way that aligned their rewards with an increase in stockholder value. Not given to them for existing while we see no increase in profits year over year and a decrease in stock price of more than 10 dollars per share during the past 12 months. They seem to be lining their pockets without reaching measurable goals. I still hope that they will accomplish a positive settlement with Nokia to earn the rewards they have already recived.
please keep up your good work. We need it!
LIke others have said it can't be considered a positive unless you want to increase your holdings at a lower price.
Ron
test